Who is sponsoring NCT00290264?

NCT00290264 is sponsored by AstraZeneca.

What drugs are being tested in NCT00290264?

Interventions: Budesonide/formoterol.

What is the status of NCT00290264?

NCT00290264 is currently COMPLETED.

Last reviewed 2011-01-21 · How we verify

A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbohaler 160/4.5 μg, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults - a 26-week, Randomised, Open-label, Parallel-group, Multi-centre Study (SALTO)

NCT00290264 Phase 3 COMPLETED

The primary objective is to compare the efficacy of Symbicort Single inhaler Therapy with treatment according to conventional best practice in adolescent and adult patients with persistent asthma.

Details

Lead sponsor	AstraZeneca
Phase	Phase 3
Status	COMPLETED
Enrolment	1000
Start date	2004-12
Completion	2006-08

Conditions

Asthma

Interventions

Budesonide/formoterol

Primary outcomes

Time to first severe asthma exacerbation

Countries

Belgium, Luxembourg